Dear Editor, Social anxiety disorder (SAD) is one of the most common and debilitating types of anxiety disorders. Nevertheless, little attention has been dedicated to the study of the neurobiology underlying SAD until the last decade. 1 Approximately 25% of anxiety disorder patients, including SAD patients, are nonresponders to traditional methods of treatment. 2 Thus, advances in our understanding of the neural basis involved in SAD could lead to new therapeutic options. 1 One such novel therapeutic option is repetitive transcranial magnetic stimulation (rTMS), a lates electrical activity in the brain and depolarizes neurons. 2 We report a case of a 38 year old single male. The patient signed a consent form and was aware of the experimental protocol (approved by the Ethics Committee at Universidade Federal do Rio de Janeiro) before participation commenced. in public), without comorbidities according to DSM-IV-TR. reuptake inhibitor (SSRI) and cognitive behavior therapy (CBT). A single session of rTMS was administered at 1Hz (inhibitory frequency) at 120% MT for 25 min (1,500 pulses) over the right ventromedial prefrontal cortex (vmPFC). The vmPFC represents the most promising target for rTMS because this structure is consistently activated in SAD. 1 The right vmPFC is located near the Fp2 position according to an EEG-international 10/20 electrode scalp positioning system. Through this system, satisfactory activation of cortical areas may be reached reliably on a larger scale. 3 Assessments were carried out pre-and post-treatment using the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI) and Social Skills Inventory (SSI). Pre-treatment results were the following: BDI 18 (moderate), BAI 21 (moderate). Post-treatment results were the following: BDI 19 (moderate), BAI 5 (minimal). At a 2-month follow-up, we obtained the following results: BDI 13 (minimal) and BAI 13 (mild) ( Figure 1A) . With respect to SSI, there were changes in social skill performance in 12 (8 positives and 4 negatives) of 32 issues between the pre-treatment and the post-treatment periods and in 16 (10 positives and 6 negatives) of 32 issues between the post-treatment and the follow-up periods ( Figure 1B 
